Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

1.0K
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
1.0K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.6K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.6K
Epistaxis01:30

Epistaxis

740
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
740
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

764
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
764
Acute Pharyngitis01:30

Acute Pharyngitis

6.0K
Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
6.0K
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

657
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
657

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Success of Anterior Ethmoidal Artery Flaps for Nasal Septal Perforation Repair: A Systematic Review.

The Laryngoscope·2026
Same author

Longitudinal SNOT-22 Symptom Changes With Sublingual Immunotherapy (SLIT).

The Laryngoscope·2026
Same author

Enhancing Operative Documentation in Rhinology: Surgical Navigation as a Practical Adjunct.

International forum of allergy & rhinology·2026
Same author

Anterior Ethmoid Artery Ligation for Epistaxis: A Systematic Review.

Laryngoscope investigative otolaryngology·2026
Same author

Neoadjuvant Immunotherapy in the Management of Cutaneous Squamous Cell Carcinoma.

Skin therapy letter·2025
Same author

Evaluation of Disparities in Management of Chronic Rhinosinusitis by Race and Ethnicity: An All of Us Research Program Study.

American journal of rhinology & allergy·2025

Related Experiment Video

Updated: Apr 7, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.7K

Association Between Biologic Therapy and Reduced Acute Rhinosinusitis Episodes: A Retrospective Database Study.

Wynne Zheng1, Maeen Arslan1, Christina Zhu1

  • 1Georgetown University School of Medicine Washington DC USA.

Laryngoscope Investigative Otolaryngology
|April 6, 2026
PubMed
Summary
This summary is machine-generated.

Biologics like dupilumab significantly reduced acute bacterial rhinosinusitis (ABRS) episodes in patients without chronic rhinosinusitis with nasal polyps (CRSwNP). Dupilumab showed the most significant protective effect on sinonasal health.

Keywords:
acute rhinosinusitisbiologic medicationchronic rhinosinusitisnasal polyps

More Related Videos

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.9K
Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

32.5K

Related Experiment Videos

Last Updated: Apr 7, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.7K
Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.9K
Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

32.5K

Area of Science:

  • Immunology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Biologics are increasingly used for various inflammatory conditions.
  • The impact of biologics on sinonasal health, particularly acute bacterial rhinosinusitis (ABRS), is not fully understood in non-CRSwNP populations.
  • Understanding potential off-target benefits of biologics is crucial for comprehensive patient care.

Purpose of the Study:

  • To investigate if biologics (dupilumab, mepolizumab, omalizumab) reduce ABRS episodes in patients without chronic rhinosinusitis with nasal polyps (CRSwNP).
  • To evaluate the comparative effectiveness of different biologics in preventing ABRS in this specific patient group.

Main Methods:

  • Retrospective cohort study using the All of Us Research Program database.
  • Identified patients treated with dupilumab, mepolizumab, or omalizumab, excluding those with CRSwNP.
  • Propensity score matching (1:1) and K-nearest neighbors were used to create a control group matched for demographics and comorbidities.
  • Primary outcome: frequency of ABRS episodes, analyzed using chi-squared tests to calculate odds ratios (ORs) and 95% confidence intervals (CIs).

Main Results:

  • A total of 2094 subjects were analyzed.
  • The biologic group showed a significantly lower ABRS rate (6%) compared to controls (14%) (OR 0.4349, p < 0.0001).
  • Dupilumab demonstrated the most significant reduction in ABRS risk (OR 0.1526, p < 0.001044).
  • Mepolizumab and omalizumab showed a trend towards decreased ABRS episodes, but results were not statistically significant.

Conclusions:

  • Dupilumab significantly reduces ABRS episodes in patients without CRSwNP, indicating a potential protective effect on sinonasal health.
  • These findings suggest biologics may offer benefits beyond their primary indications.
  • Further research is warranted to confirm these effects and assess long-term safety in non-CRSwNP populations.